Clinical Trial Radar

Name: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Creator: Novo Nordisk A/S
Published: 2023-10-04
License: https://www.clinicaltrials.gov/about-site/terms-conditions#availability

beta

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Clinical Trial NCT06065540 (REIMAGINE 2) for Type 2 Diabetes Mellitus is completed. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.

One study matched filter criteria

Card View

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2) Phase 3 2,734

Completed

Clinical Trial NCT06065540 (REIMAGINE 2) was designed to study Treatment for Type 2 Diabetes Mellitus. This was a Phase 3 interventional study that is now completed. The study started on 27 September 2023, with plans to enroll 2,734 participants. Led by Novo Nordisk A/S, the expected completion date was 6 January 2026. The latest data from ClinicalTrials.gov was last updated on 22 January 2026.

Brief Summary

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in particip...Show More

Official Title

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Conditions

Type 2 Diabetes Mellitus

Other Study IDs

REIMAGINE 2
NN9388-4896
U1111-1283-0427 (Other Identifier) (World Health Organization (WHO))
2022-502678-18 (EudraCT Number)

NCT ID Number

NCT06065540

Start Date (Actual)

2023-09-27

Last Update Posted

2026-01-22

Completion Date (Estimated)

2026-01-06

Enrollment (Estimated)

2,734

Study Type

Interventional

PHASE

Phase 3

Status

Completed

Primary Purpose

Treatment

Design Allocation

Randomized

Interventional Model

Parallel

Masking

Quadruple

Arms / Interventions

Participant Group/Arm	Intervention/Treatment
ExperimentalCagriSema Dose 1 Participants will receive once-weekly subcutaneous (s.c) injections of cagrilintide dose 1 and semaglutide dose 1 for 68 weeks.	Cagrilintide Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached. Semaglutide Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
ExperimentalCagriSema Dose 2 Participants will receive once-weekly s.c injections of cagrilintide dose 2 and semaglutide dose 2 for 68 weeks.	Cagrilintide Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached. Semaglutide Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
Active ComparatorSemaglutide Dose 1 Participants will receive once-weekly s.c injection of semaglutide dose 1 for 68 weeks.	Semaglutide Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
Active ComparatorSemaglutide Dose 2 Participants will receive once-weekly s.c injection of semaglutide dose 2 for 68 weeks.	Semaglutide Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
Active ComparatorCagrilintide Dose 1 Participants will receive once-weekly s.c injection of cagrilintide dose 1 for 68 weeks.	Cagrilintide Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
Placebo ComparatorPlacebo Dose 1 Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 1 and semaglutide dose 1 for 68 weeks.	Placebo cagrilintide Participants will receive placebo matched to cagrilintide subcutaneously. Placebo semaglutide Participants will receive placebo matched to semaglutide subcutaneously.
Placebo ComparatorPlacebo Dose 2 Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 2 and semaglutide dose 2 for 68 weeks.	Placebo cagrilintide Participants will receive placebo matched to cagrilintide subcutaneously. Placebo semaglutide Participants will receive placebo matched to semaglutide subcutaneously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)	Measured in percentage-points.	From baseline (week 0) to end of treatment (week 68)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CagriSema versus cagrilintide: Change in HbA1c	Measured in percentage-points.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus cagrilintide: Relative change in body weight	Measured in percentage.	From baseline (week 0) to end of treatment (week 68)
CagriSema (dose 1) versus semaglutide (dose 2): Change in HbA1c	Measured in percentage-points.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Relative change in body weight	Measured in percentage.	From baseline (week 0) to end of treatment (week 68)
Cagrilintide versus placebo: Change in HbA1c	Measured in percentage-points.	From baseline (week 0) to end of treatment (week 68)
Cagrilintide versus placebo: Relative change in body weight	Measured in percentage.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of greater than or equal to (>=) 10 percent (%) weight reduction	Measured as count of participants.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of >= 15 % weight reduction	Measured as count of participants.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of >= 20 % weight reduction	Measured as count of participants.	From baseline (week 0) to end of treatment (week 68)
CagriSema (pooled doses) versus semaglutide (pooled doses): Continuous Glucose Monitoring (CGM) - Change in Time in Range (TIR) 3.9-10.0 millimoles per litre (mmol/L) (70-180 milligrams per decilitre [mg/dL])	Measured in percentage-points.	From baseline (week -3) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 (mmol/L) (70-140 mg/dL)	Measured in percentage-points.	From baseline (week -3) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Systolic Blood Pressure (SBP)	Measured in millimeters of mercury (mmHg).	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in triglycerides	Measured as ratio of triglycerides.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols	Measured as ratio of non-HDL cholesterol.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)	Measured in percentage-points.	From baseline (week -3) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)	Measured as ratio of hsCRP.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Fasting Plasma Glucose (FPG)	Measured in mmol/L.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])	Measured as count of participants.	At end of treatment (week 68)
CagriSema versus semaglutide: Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol)	Measured as count of participants.	At end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL)	Measured in percentage-points.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL)	Measured in percentage-points.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Within-day glycaemic variability (% coefficient of variation [CV])	Measured in percentage.	At end of treatment (week 68)
CagriSema versus semaglutide: Achievement of ≥ 5 % weight reduction	Measured as count of participants.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in waist circumference	Measured in centimetre.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Diastolic Blood Pressure (DBP)	Measured in mmHg.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in total cholesterol	Measured as ratio of total cholesterol.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in HDL cholesterol	Measured as ratio of HDL cholesterol.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in low-density lipoprotein (LDL) cholesterol	Measured as ratio of LDL cholesterol.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol	Measured as ratio of VLDL.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in free fatty acids	Measured as ratio of free fatty acids.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Short Form (SF)-36v score- Physical component summary score	SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Physical component summary score range from 6.1 to 79.7, with higher scores indicating better functional health and well-being.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in SF-36v2 score- Mental component summary score	SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Mental component summary score range from -3.8 to 78.7, with higher scores indicating better functional health and well-being.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score	DTSQc measures treatment satisfaction and diabetes-specific quality of life (QoL). The measure consists of 8 items yielding 1 global score and 2 single item scores. Total treatment satisfaction scores range from 0-36, with higher scores indicating greater satisfaction; the perceived frequency of hyperglycemia/hypoglycemia items are scored separately, with lower scores indicating better perceived blood glucose control.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score	TRIM-D measures impact of diabetes treatment. The measure consists of 28 items yielding 5 domain scores and a total score. The scores were transformed to a 0-100 scale with higher scores indicating a better health state.	From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide, placebo and cagrilintide: Number of treatment emergent adverse events (TEAEs)	Measured as count of events.	From baseline (week 0) to end of study (week 75)
CagriSema versus semaglutide: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)	Measured as count of episodes.	From baseline (week 0) to end of study (week 75)
CagriSema versus semaglutide: Number of severe hypoglycaemic episodes (level 3)	Measured as count of episodes. Hypoglycaemia episodes (level 3) are the episodes associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold.	From baseline (week 0) to end of study (week 75)

Eligibility Criteria

Eligible Ages

Adult, Older Adult

Minimum Age

18 Years

Eligible Sexes

All

Male or female (sex at birth).
Age 18 years or above at the time of signing the informed consent.
Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening.
Stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors.
Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening.
Body Mass Index (BMI) greater than or equal to 25 kilogram per square metre ( kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square metre (mL/min/1.73 m^2) as determined by central laboratory at screening.
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.

Novo Nordisk A/S

No contact data.

405 Study Locations in 32 Countries

Australia

New South Wales

Charles Perkins Centre, Camperdown, New South Wales, 2050, Australia

Momentum Clinical Research Darlinghurst, Darlinghurst, New South Wales, 2010, Australia

Macquarie University, Macquarie Park, New South Wales, 2109, Australia

Hunter Diabetes Centre, Merewether, New South Wales, 2291, Australia

Queensland

Logan Hospital, Meadowbrook, Queensland, 4131, Australia

South Australia

Southern Adelaide Diabetes & Endocrine Services, Oaklands Park, South Australia, 5046, Australia

Victoria

St Vincent's Hospital - Melbourne, Fitzroy, Victoria, 3065, Australia

Baker Heart and Diabetes Institute, Melbourne, Victoria, 3004, Australia

United States

Alabama

Synexus Clin Res-Birmingham, Birmingham, Alabama, 35211, United States

Univ of Alabama_Birmingham, Birmingham, Alabama, 35294, United States

Cahaba Research, Pelham, Alabama, 35124, United States

Arizona

Velocity Clinical Research-Phoenix, Phoenix, Arizona, 85006, United States

Synexus Rsch /Cnt Phnx Med C, Phoenix, Arizona, 85020, United States

Arkansas

Arkansas Clinical Research, Little Rock, Arkansas, 72205, United States

California

Velocity Clinical Res-Banning, Banning, California, 92220, United States

Velocity Clin Res-Chula Vista, Chula Vista, California, 91911, United States

John Muir Physicians Network, Concord, California, 94520, United States

Headlands Research California, LLC, Escondido, California, 92025, United States

Velocity Clin Res Gardena, Gardena, California, 90247, United States

Velocity Clin Res San Diego, La Mesa, California, 91942, United States

Loma Linda Univ Hlth Cr Endo, Loma Linda, California, 92354, United States

Facey Medical Foundation, Mission Hills, California, 91345, United States

Desert Oasis Hlthcr Med Group, Palm Springs, California, 91355, United States

Desert Oasis Hlthcr Med Group, Palm Springs, California, 92262, United States

Velocity Clin Res- San Bern, San Bernardino, California, 92408, United States

Linda Vista Health Care Ctr, San Diego, California, 92111, United States

Velocity Clin Res Santa Ana, Santa Ana, California, 92704, United States

Premier Medical Center, Inc., Toluca Lake, California, 91602, United States

Velocity Clin Res - Panorama, Van Nuys, California, 91405, United States

Colorado

Optumcare Clinical Trials,LLC-Golden, Colorado Springs, Colorado, 80906, United States

Florida

Northeast Research Institute, Jacksonville, Florida, 32204, United States

Clinical Trial Services Corp, Miami, Florida, 33144, United States

Bioclinical Research Alliance, Miami, Florida, 33155, United States

New Horizon Research Center, Miami, Florida, 33165, United States

South Broward Research LLC, Miramar, Florida, 33027, United States

West Orange Endocrinology, Ocoee, Florida, 34761, United States

Optimal Research Sites, Orange City, Florida, 32763, United States

Advent Health-Res Inst, Orlando, Florida, 32804, United States

AdventHealth Diab Inst, Orlando, Florida, 32804, United States

Synexus Clin Res - Orlando, Orlando, Florida, 32806, United States

Oviedo Medical Research, LLC, Oviedo, Florida, 32765, United States

Georgia

Hope Clin Res & Wellness, Conyers, Georgia, 30094, United States

East Coast Institute for Res, Macon, Georgia, 31210, United States

Urban Family Practice Assoc, Marietta, Georgia, 30067, United States

Endocrine Research Solutions, Inc., Roswell, Georgia, 30076, United States

Endocrine Research Solutions, Roswell, Georgia, 30076, United States

Hawaii

Pacific Diabetes & Endo Ctr, Honolulu, Hawaii, 96813, United States

Idaho

St. Luke's Health System, Boise, Idaho, 83702, United States

Solaris Clinical Research, Meridian, Idaho, 83646, United States

Illinois

Cedar-Crosse Research Center, Chicago, Illinois, 60607, United States

Clinical Invest Special_Gurnee, Gurnee, Illinois, 60031, United States

Endeavor Health, Skokie, Illinois, 60077, United States

Evanston Premier Hlthcr Res, Skokie, Illinois, 60077, United States

Iowa

Iowa Diabetes & Endo Res Ctr, West Des Moines, Iowa, 50266, United States

Kansas

Alliance for Multispec Res, Newton, Kansas, 67114, United States

Cotton-O'Neil Diab & Endo Ctr, Topeka, Kansas, 66606, United States

Louisiana

Velocity Clin Res Lafayette, Lafayette, Louisiana, 70508, United States

Massachusetts

BTC of New Bedford, LLC, New Bedford, Massachusetts, 02740, United States

Mississippi

Velocity Clin Res Gulfport, Gulfport, Mississippi, 39503, United States

Missouri

Diabetes & Endo Specialists Inc, Chesterfield, Missouri, 63017, United States

New Jersey

Premier Research Inc., Trenton, New Jersey, 08611, United States

New Mexico

Velocity Clin Res Albuquerque, Albuquerque, New Mexico, 87107, United States

New York

AMC Community Endocrinology, Albany, New York, 12203, United States

Velocity Clin Res Syracuse, East Syracuse, New York, 13057, United States

Southgate Medical Group, LLP, West Seneca, New York, 14224, United States

Great Lakes Medical Research, Westfield, New York, 14787, United States

North Carolina

University of North Carolina, Chapel Hill, North Carolina, 27514, United States

PharmQuest Life Sciences LLC, Greensboro, North Carolina, 27408, United States

Carteret Medical Group, Morehead City, North Carolina, 28557, United States

Piedmont Healthcare/Research, Statesville, North Carolina, 28625, United States

Accellacare, Wilmington, North Carolina, 28401, United States

Ohio

Radiant Research Inc. - Akron, Akron, Ohio, 44311, United States

Centricity Research, Columbus, Ohio, 43213, United States

Oklahoma

Alliance for Multispec Res, Norman, Oklahoma, 73069, United States

Rhode Island

Clinical Res Collaborative, Cumberland, Rhode Island, 02864, United States

Velocity Clin Res Providence, East Greenwich, Rhode Island, 02818, United States

South Carolina

AnMed Health IMA, Anderson, South Carolina, 29621, United States

Synexus Clin Res US-Anderson, Anderson, South Carolina, 29621, United States

Velocity Clinical Res-Anderson, Anderson, South Carolina, 29621, United States

Velocity Clin Res Gaffney, Gaffney, South Carolina, 29340, United States

Hillcrest Clinical Research, Simpsonville, South Carolina, 29681-1538, United States

Spartanburg Medical Research, Spartanburg, South Carolina, 29303, United States

Velocity Clin Res Spartanburg, Spartanburg, South Carolina, 29303, United States

Tennessee

Holston Medical Group Pc, Bristol, Tennessee, 37620-7352, United States

Holston Medical Group, Kingsport, Tennessee, 37660, United States

Clinical Research Associates, Nashville, Tennessee, 37203, United States

Texas

Arlington Family Res. Ctr Inc, Arlington, Texas, 76012-4637, United States

Velocity Clin Res Austin, Austin, Texas, 78759, United States

UT Health University of Texas, Bellaire, Texas, 77401, United States

Velocity Clinical Res-Dallas, Dallas, Texas, 75230, United States

North Texas Endocrine Center, Dallas, Texas, 75231, United States

Synexus Clin Res Dallas, Dallas, Texas, 75234, United States

Cedar Health Research, Dallas, Texas, 75251, United States

JCCT- Juno NW Houston, Houston, Texas, 77040, United States

Synergy Groups Medical, Houston, Texas, 77061, United States

PlanIt Research, PLLC, Houston, Texas, 77079, United States

Medical Colleagues-Texas LLP, Katy, Texas, 77450, United States

Sante Clinical Research, Kerrville, Texas, 78028, United States

Discovery MMS Services, INC, Missouri City, Texas, 77459, United States

AES San Antonio, San Antonio, Texas, 78229, United States

University of Texas San Antonio, San Antonio, Texas, 78229, United States

NE Clin Res of San Antonio, San Antonio, Texas, 78233, United States

Consano Clinical Research, LLC, Shavano Park, Texas, 78231, United States

DM Clin Rsrch/Fam Diag Clinic, Tomball, Texas, 77375, United States

Utah

Diabetes & Endo Treatment Spec, Sandy City, Utah, 84093, United States

Velocity Clin Res-Salt Lk City, West Jordan, Utah, 84088, United States

Virginia

TPMG Clinical Research, Newport News, Virginia, 23606, United States

Washington

Rainier Clin Res Ctr Inc, Renton, Washington, 98057, United States

Wisconsin

St. Vincent Hosp-Prevea Health, Green Bay, Wisconsin, 54303, United States

Argentina

Buenos Aires

Mautalen Salud e investigación, CABA, Buenos Aires, C1128 AAF, Argentina

City of Buenos Aires

Sanatorio Güemes, CABA, City of Buenos Aires, C1180AAX, Argentina

Santa Fe Province

Instituto de Investigaciones Clínicas Rosario, Rosario, Santa Fe Province, S2000CUD, Argentina

STAT Research, Buenos Aires, C1023AAB, Argentina

Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli, Buenos Aires, C1425AGC, Argentina

Centro de Investigación y Prevención Cardiovascular, CABA, C1061AAS., Argentina

Brazil

Paraná

Cline Research Center, Curitiba, Paraná, 80030-480, Brazil

São Paulo

CPQuali Pesquisa Clínica Ltda, São Paulo, São Paulo, 01228-000, Brazil

CPCLIN - Centro de Pesquisas Clínicas, São Paulo, São Paulo, 01228-200, Brazil

Bulgaria

IPSMC - Dr. Nikolay Kostadinov EOOD, Burgas, 8000, Bulgaria

Dr. Tatyana Metalova - AIPSMCE EOOD, Gotse Delchev, 2900, Bulgaria

ASOMCEID - Individual Practice - Dr. Abdul-Azis EOOD, Kardzhali, 6600, Bulgaria

Medical Center Zdrave Lom EOOD, Lom, 3600, Bulgaria

Medical Centre Razgrad OOD, Razgrad, 7200, Bulgaria

DCC Ascendent OOD, Sofia, 1202, Bulgaria

Medical Center Maraya Med EOOD, Sofia, 1756, Bulgaria

Medical Centre - Clinic Nova EOOD, Varna, 9000, Bulgaria

Medical centre Clinic Nova, Varna, 9000, Bulgaria

UMHAT Sveta Marina EAD, Varna, 9010, Bulgaria

Canada

Alberta

Centricity Research Calgary Endocrinology, Calgary, Alberta, T2H 2G4, Canada

Centricity Research Calgary, Calgary, Alberta, T2H 2G4, Canada

Synergy Wellness Clinic, Sherwood Park, Alberta, T8H 0N2, Canada

British Columbia

Guilford Med Clinic, Surrey, British Columbia, V3R 4H6, Canada

TLC Diabetes and Endocrinology, Surrey, British Columbia, V3T 2V6, Canada

Ocean West Research Clinic, Surrey, British Columbia, V3Z 2N6, Canada

Hilltop Medical Clinic, Surrey, British Columbia, V4A 0C1, Canada

Spectrum Health Clinic, Vancouver, British Columbia, V6Z 2T1, Canada

New Brunswick

G.A. Research Associates Ltd., Moncton, New Brunswick, E1G 1A7, Canada

Ontario

Centricity Res. Barrie Endo, Barrie, Ontario, L4N 7L3, Canada

Centricity Research Brampton Endocrinology, Brampton, Ontario, L6S 0C6, Canada

Centricity Research Vaughn Endocrinology, Concord, Ontario, L4K 4M2, Canada

Medical Trust Clinics, Inc., Courtice, Ontario, L1E2J5, Canada

Centricity Research Etobicoke Endocrinology, Etobicoke, Ontario, M9R 4E1, Canada

Milestone Research, London, Ontario, N5W 6A2, Canada

Western Univ. Cnt for Studies in Fam Med, London, Ontario, N6G 2M1, Canada

My Endo Diabetes & Endo Cent, Markham, Ontario, L3P 7P2, Canada

Centricity Research Ottawa LMC, Nepean, Ontario, K2J 0V2, Canada

Centricity Research Oshawa, Oshawa, Ontario, L1J 2K9, Canada

Centricity Research Toronto, Toronto, Ontario, M4G 3E8, Canada

Diabetes Heart Research Centre, Toronto, Ontario, M6G 1M2, Canada

Quebec

Centre Medical Acadie, Montreal, Quebec, H4N 2W2, Canada

Centricity Res Pointe-Claire, Pointe-Claire, Quebec, H9R 4S3, Canada

ALPHA Recherche Clinique, Québec, Quebec, G3K 2P8, Canada

LMC Clin Rsrch Inc. (Montreal), Saint-Laurent, Quebec, H4T 1Z9, Canada

Q & T Research Sherbrooke Inc., Sherbrooke, Quebec, J1J 2G2, Canada

Ctr de Med Metab de Lanaudiere, Terrebonne, Quebec, J6X 4P7, Canada

Diex Recherche Victoriaville, Victoriaville, Quebec, G6P 3Z8, Canada

Diex Recherche Quebec Inc., Québec, G1V 4T3, Canada

Clin des Mal Lipid de Quebec, Québec, G1V 4W2, Canada

Centre de Recherche Saint-Louis, Québec, G1W 4R4, Canada

China

Beijing Municipality

Beijing Friendship Hospital, Capital Medical University-Endocrinology, Beijing, Beijing Municipality, 100050, China

Chinese People's Liberation Army General Hospital-Endocrinology, Beijing, Beijing Municipality, 100853, China

Chongqing Municipality

Chongqing University Three Gorges Hospital, Chongqing, Chongqing Municipality, 404000, China

Henan

Huaihe Hospital of Henan University-Endocrinology, Kaifeng, Henan, 475000, China

Jiangsu

The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing, Jiangsu, 210011, China

Suzhou Municipal Hospital-Endocrinology, Suzhou, Jiangsu, 215002, China

The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang, Jiangsu, 212001, China

Shandong

Jinan Central Hospital, Ji'Nan, Shandong, 250000, China

Jinan Central Hospital, Jinan, Shandong, 250000, China

Colombia

Santander Department

FOSCAL, Floridablanca, Santander Department, 681004, Colombia

Cimedical, Barranquilla, 80001, Colombia

Clinica Imbanco SAS, Cali, 760042, Colombia

IMAT - Oncomedica, Montería, 230001, Colombia

Croatia

City of Zagreb

Poliklinika Solmed, Zagreb, City of Zagreb, 10000, Croatia

County of Osijek-Baranja

Poliklinika SLAVONIJA OSIJEK, Osijek, County of Osijek-Baranja, 31000, Croatia

Primorje-Gorski Kotar County

Clinical Hospital Centre Rijeka_Endocrinology, Rijeka, Primorje-Gorski Kotar County, 51 000, Croatia

Specijalna bolnica Thalassotherapia, Opatija, 51 410, Croatia

General Hospital Dr. Josip Bencevic_Diabetic department, Slavonski Brod, 35 000, Croatia

Opca bolnica Varazdin_Endocrinology, Varaždin, 42 000, Croatia

Czechia

Czech Republic

IKEM Centrum Diabetologie, Prague, Czech Republic, 140 21, Czechia

Fakultní nemocnice U sv. Anny v Brně, Brno, 602 00, Czechia

Edumed Broumov, Broumov, 550 01, Czechia

Diahaza s.r.o., Holešov, 76901, Czechia

DIALINE s.r.o., Plzeň 3, 301 00, Czechia

Diabet2 s.r.o., Prague, 110 00, Czechia

MUDr. Michala Pelikanova, Prague, 140 00, Czechia

Denmark

Aarhus Universitetshospital, Steno Diabetes Center Aarhus, Aarhus N, 8200, Denmark

Bispebjerg Hospital, IC-Forskning, Copenhagen, 2400, Denmark

Steno Diabetes Center Copenhagen, Herlev, 2730, Denmark

Hillerød Endokrinologisk amb. H0652, Hillerød, 3400, Denmark

Hvidovre Hospital Endokrinologisk forsk. afs. 159, Hvidovre, 2650, Denmark

Steno Diabetes Center Odense, Odense C, 5000, Denmark

Finland

Terveystalo Jyväskylä, Jyväskylä, 40100, Finland

Seinäjoen keskussairaala, Seinäjoki, 60220, Finland

Pihlajalinna Koskiklinikka, Tampere, 33100, Finland

Terveystalo Tampere Rautatienkatu, Tampere, 33100, Finland

Turku University Hospital, Turku, 20520, Finland

Germany

Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR, Berlin, 13597, Germany

Diabetologische Schwerpunktpraxis Daaden, Daaden, 57567, Germany

Diabeteszentrum-Do Dres. K U. Ch. Busch GbR, Dortmund, 44137, Germany

Uniklinik TU Dresden - Med. Klinik III, Dresden, 01307, Germany

Zentrum fuer klinische Studien Suedbrandenburg GmbH, Elsterwerda, 04910, Germany

InnoDiab Forschung GmbH, Essen, 45136, Germany

MVZ Diabeteszentrum Dr. Tews GmbH, Gelnhausen, 63571, Germany

Diabetes-Zentrum-Wilhelmsburg GbR, Hamburg, 21109, Germany

Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR, Hamburg, 22041, Germany

Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz, Lingen, 49808, Germany

Die Praxis am Ludwigsplatz, Ludwigshafen, 67059, Germany

Uniklinik Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck, Lübeck, 23538, Germany

Medicover Neuroendokrinologie MVZ München, München, 81667, Germany

RED-Institut für medizinische Forschung und Fortbildung GmbH, Oldenburg in Holstein, 23758, Germany

Praxis für Innere Medizin - Zwenkau, Zwenkau, 04442, Germany

Greece

Attica

University Hospital of Athens ATTIKON, Athens, Attica, 12462, Greece

Thessaloniki

General Hospital Of Thessaloniki Papageorgiou, Nea Efkarpia, Thessaloniki, 56429, Greece

Iatriko Psychicou Private Clinic, Athens, 115 25, Greece

"Laiko" General Hospital of Athens, Athens, 11527, Greece

General hospital of Athens 'G.Gennimatas', Athens, 11527, Greece

Iatriko Athinon (Athens Medical Canter), Athens, 15125, Greece

Univ Gen Hospital Larisa, Larissa, 41110, Greece

"AHEPA" University Hospital of Thessaloniki, Thessaloniki, 54621, Greece

NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes, Thessaloniki, 54635, Greece

"AHEPA" University Hospital of Thessaloniki, Thessaloniki, 54636, Greece

"Ippokrateio" G.H. of Thessaloniki, Thessaloniki, 54642, Greece

Hungary

Csongrád-Csanád

Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ, Szeged, Csongrád-Csanád, 6725, Hungary

Hajdú-Bihar

Debreceni Egyetem Belgyógyászati Klinika, Debrecen, Hajdú-Bihar, 4032, Hungary

Pest County

Óbudai Egészségügyi Centrum, Budapest, Pest County, 1036, Hungary

Bajcsy-Zsilinszky Kórház, Budapest, 1106, Hungary

MH Egészségügyi Központ, Budapest, 1134, Hungary

Kaposi Mór Oktató Kórház, Kaposvár, 7400, Hungary

Kanizsai Dorottya Kórház, Nagykanizsa, 8800, Hungary

Vas Vármegyei Markusovszky Egyetemi Oktatókórház, Szombathely, 9700, Hungary

Zala Megyei Szent Rafael Kórház, Zalaegerszeg, 8900, Hungary

India

Andhra Pradesh

Yalamanchi Hospitals and Research centres pvt ltd, Vijaywada, Andhra Pradesh, 520002, India

Assam

Gauhati Medical College and Hospital, Guwahati, Assam, 781032, India

Gujarat

Swasthya Diabetes Care, Ahmedabad, Gujarat, 390013, India

Karnataka

Lifecare Hospital and Research Centre, Bengaluru, Karnataka, 560066, India

K R Hospital, Mysuru, Karnataka, 570001, India

Maharashtra

BYL Nair Hospital and T N Medical College Department of endo, Mumbai, Maharashtra, 400008, India

Ashirwad Hospital and Research Centre, Thane, Maharashtra, 421004, India

Rajasthan

SMS Medical College & Hospital, Jaipur, Rajasthan, 302004, India

Tamil Nadu

Madras Diabetes Research Foundation, Chennai, Tamil Nadu, 600086, India

KG Hospital, Coimbatore, Tamil Nadu, 641018, India

Telangana

Gleneagles Hospitals, Hyderabad, Telangana, 500004, India

Dr P V Rao - Diabetes Research Centre, Hyderabad, Telangana, 50082, India

West Bengal

Apollo Multispeciality Hospital, Kolkata, Kolkata, West Bengal, 700054, India

Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India

Lady Hardinge Medical College, New Delhi, 110001, India

Israel

Clalit sick fund Herzeliya, Herzeliya, Israel, 4630945, Israel

Linn clinic - Clalit Health Services, Haifa, 35152, Israel

Linn clinic - Diabetes Unit, Haifa, 35152, Israel

Clalit sick fund Herzlia, Herzliya, 4630945, Israel

Wolfson MC - Diabetes Clinic, Holon, 58100, Israel

Hadassah Ein Karam MC - Diabetes Unit, Jerusalem, 91120, Israel

Kaplan MC - Metabolic Unit, Rehovot, 76100, Israel

Kaplan MC, Rehovot, 76100, Israel

Sheba MC - Endocrinology Clinic, Tel Litwinsky, 52621, Israel

Italy

AOU Careggi Firenze, Florence, Fi, 50134, Italy

Istituto Scientifico San Raffaele, Milan, MI, 20132, Italy

Tuscany

AOU Careggi Firenze, Florence, Tuscany, 50134, Italy

Azienda Sanitaria Usl Toscana Sud Est - Ospedale San Donato, Arezzo, 52100, Italy

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, 24127, Italy

Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, 88100, Italy

Università degli studi G. D'Annunzio Chieti Pescara - CAST, Chieti Scalo, 66100, Italy

Azienda Ospedaliera Luigi Sacco, Milan, 20157, Italy

Azienda Ospedaliera Universitaria Federico II di Napoli, Naples, 80131, Italy

AOUP Giaccone Palermo, Palermo, 90127, Italy

Dip. di Medicina Interna Policlinico Universitario Palermo, Palermo, 90127, Italy

Azienda Ospealiero Universitaria Policlinico Umberto I, Roma, 00161, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Dipartimento di scienze Mediche e Chirurgiche, Rome, 00168, Italy

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Civile Maggiore Borgo Trento, Verona, 37126, Italy

Japan

Fukushima, Japan

Seino Internal Medicine Clinic_Internal medicine, Koriyama-shi, Fukushima, Fukushima, Japan, 963-8851, Japan

Oita, Japan

Abe Diabetes Clinic_Internal Medicine, Ōita, Oita, Japan, 870 0039, Japan

Akaicho Clinic, Chiba-shi, Chiba, 260-0804, Japan

Naka Kinen Clinic_Internal medicine, Ibaraki, 311-0113, Japan

Naka Kinen Clinic, Ibaraki, 311-0113, Japan

Minami Akatsuka Clinic, Mito-shi, Ibaraki, 311-4153, Japan

Medical Research Institute KITANO HOSPITAL_Diabetes & Endocrinology, Osaka-shi, Osaka, 530-8480, Japan

Tokyo-Eki Center-building Clinic_Internal Medicine, Tokyo, 103-0027, Japan

Fukuwa Clinic_Internal Medicine, Tokyo, 104-0031, Japan

Fukuwa Clinic, Tokyo, 104-0031, Japan

Mexico

Estado de Baja California

Centro de investigación en Artritis y Osteoporosis S.C., Mexicali, Estado de Baja California, 21200, Mexico

Jalisco

InstitutoJalisciense de Investigación en Diabetes y Obesidad, Guadalajara, Jalisco, 44600, Mexico

Centro de Investigacion Clinica Endocrinologica de Jalisco, Guadalajara, Jalisco, 44670, Mexico

Tamaulipas

Centro de Estudios de Investigación Metabólicos y Cardio, Ciudad Madero, Tamaulipas, 89440, Mexico

Poland

Lesser Poland Voivodeship

Malopolskie Centrum Sercowo-Naczyniowe, Chrzanów, Lesser Poland Voivodeship, 32-500, Poland

Lubusz Voivodeship

Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski, Gorzów Wielkopolski, Lubusz Voivodeship, 66-400, Poland

Masovian Voivodeship

Prywatna Praktyka Lekarska Anna Chudoba, Żyrardów, Masovian Voivodeship, 96-300, Poland

Mazovian Voivodeship

Instytut Diabetologii Sp. z o.o., Warsaw, Mazovian Voivodeship, 02-117, Poland

Podkarpackie Voivodeship

Centrum Medyczne Medyk Sp. z o.o., Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

Podlaskie Voivodeship

Osteo Medic s.c. Artur Racewicz Jerzy Supronik, Bialystok, Podlaskie Voivodeship, 15-351, Poland

NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska, Bialystok, Podlaskie Voivodeship, 15-435, Poland

Silesian Voivodeship

PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii, Dąbrowa Górnicza, Silesian Voivodeship, 41-300, Poland

PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii, Tychy, Silesian Voivodeship, 43-100, Poland

Centrum Medyczne Pratia Bydgoszcz, Bydgoszcz, 85-796, Poland

PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii, Dąbrowa Górnicza, 41-300, Poland

Velocity Nova Sp. z o.o., Lublin, 20-362, Poland

KO-MED Centra Kliniczne Sp. z o.o., Puławy, 24-100, Poland

Velocity Nova Sp. z o.o., Staszów, 28-200, Poland

NBR Polska Tomasz Klodawski, Warsaw, 00-710, Poland

Instytut Diabetologii Sp. z o.o., Warsaw, 02-117, Poland

Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji, Warsaw, 02-507, Poland

Zgierskie Centrum Kardiologii Med-Pro Polsko-Amerykańskich Klinik Serca, Zgierz, 95-100, Poland

Łódź Voivodeship

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Lodz, Łódź Voivodeship, 93-513, Poland

Świętokrzyskie Voivodeship

Velocity Nova Sp. z o.o., Staszów, Świętokrzyskie Voivodeship, 28-200, Poland

Romania

Argeş

Cabinet Medical Individual Dr. Ramona Dragut SRL, Piteşti, Argeş, 110283, Romania

Bucurestii

Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila, Bucharest, Bucurestii, 020475, Romania

Cluj

Spitalul Clinic Judetean Urgenta Cluj-Napoca, Cluj-Napoca, Cluj, 400006, Romania

Mureș County

Poli Cardinal Med Srl, Reghin, Mureș County, 545300, Romania

Prahova

Diabmed Dr Popescu Alexandrina SRL, Ploieşti, Prahova, 100179, Romania

CMI Dr. Busegeanu Mihaela Magdalena, Ploieşti, Prahova, 100342, Romania

Sălaj County

Cabinet Medical de Diabet, Nutritie si Boli Metabolice-Dr. Zaharie Daniela Gabriela, Zalău, Sălaj County, 450112, Romania

CMI Dr. Pletea Noemi SRL, Bacau, 600154, Romania

Mariodiab Clinic SRL, Brasov, 500101, Romania

Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed, Brasov, 500283, Romania

Diabet Med SRL, Bucharest, 050913, Romania

Urodiamed SRL, Craiova, 200349, Romania

S.C Milena Sante SRL, Galati, 800001, Romania

Gama Diamed Srl, Mangalia, 905500, Romania

Bella Praxis S.R.L., Paşcani, 705200, Romania

Serbia

Vojvodina

Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis., Novi Sad, Vojvodina, 21000, Serbia

CHC Zvezdara, Clinical department for endocrinology, Belgrade, 11000, Serbia

Endocrinology, Diabetes and Metabolism Diseases Clinic, Belgrade, 11000, Serbia

Clinical Hospital Center Bezanijska Kosa, Belgrade, 11080, Serbia

Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department, Kragujevac, 34000, Serbia

Clinical Centre Kragujevac, Internal Diseases Clinic, Endocr, Kragujevac, 34000, Serbia

Slovakia

DIADA, s.r.o., Bardejov, 08501, Slovakia

Diabetologicka ambulancia DIOLI s.r.o., Košice, 040 01, Slovakia

DIOLI s.r.o., Košice, 040 01, Slovakia

MediVet s.r.o., Malacky, 90101, Slovakia

DIALIPID, s.r.o., Prešov, 080 01, Slovakia

MUDr. Jan Culak, s.r.o., Prievidza, 971 01, Slovakia

DIACENTRUM, s.r.o., Ružomberok, 034 01, Slovakia

MEDI-DIA s.r.o., Sabinov, 083 01, Slovakia

DEImedi, s. r. o., Šurany, 942 01, Slovakia

ARETEUS s.r.o., Trebišov, 075 01, Slovakia

iDia s. r. o., Žiar nad Hronom, 965 01, Slovakia

Slovenia

Healthcare centre Kocevje, Kočevje, 1330, Slovenia

Healthcare Centre Koper, Koper, 6000, Slovenia

Dermatologija Bartenjev, Ljubljana, 1000, Slovenia

UKC Ljubljana, Endocrinology and Diabetes, Ljubljana, 1000, Slovenia

UKC Maribor - diabetes, Maribor, 2000, Slovenia

Healthcare Centre Nova Gorica, Nova Gorica, 5000, Slovenia

General Hospital Nova Gorica_Diabetes, Šempeter pri Gorici, 5290, Slovenia

Hospital Topolšica, Topolšica, 3326, Slovenia

South Africa

Eastern Cape

Phoenix Pharma, Port Elizabeth, Eastern Cape, 6001, South Africa

Gauteng

Newtown Clinical Research, Johannesburg, Gauteng, 2001, South Africa

Sandton Medical Research, Johannesburg, Gauteng, 2196, South Africa

Clinresco Centres (Pty) Ltd, Kempton Park, Gauteng, 1619, South Africa

Clinical Trial Systems (CTC), Pretoria, Gauteng, 0186, South Africa

Western Cape

Paarl Research Centre, Paarl, Cape Town, Western Cape, 7646, South Africa

South Korea

Gyeonggi-do

The Catholic University of Korea, Bucheon ST. Mary's Hospital, Bucheon-si, Gyeonggi-do, 14647, South Korea

Yeungnam University Medical Center, Daegu, 42415, South Korea

Chosun University Hospital, Gwangju, 501-717, South Korea

Kyunghee University Medical Center, Seoul, 02447, South Korea

Korea University Anam Hospital, Seoul, 02841, South Korea

Seoul National University Hospital, Seoul, 03080, South Korea

Kangbuk Samsung Hospital, Seoul, 03181, South Korea

Spain

Complejo Hospitalario Universitario A Coruña, A Coruña, 15006, Spain

Hospital Vall d'Hebron, Barcelona, 08035, Spain

ABS La Roca del Vallés_Endocrinología, La Roca Del Vallés, 08430, Spain

Hospital Universitario de Móstoles, Móstoles, 28935, Spain

Hospital Son Llatzer, Palma de Mallorca, 07198, Spain

Hospital General de Segovia, Segovia, 40002, Spain

Hospital Infanta Luisa, Seville, 41010, Spain

Hospital La Fe - Endocrinología y Nutrición, Valencia, 46026, Spain

Sweden

CTC EbbePark Linköping, Linköping, 582 13, Sweden

Clemenstorgets Hjärtmottagning, Lund, 222 21, Sweden

Endokrinologkliniken, Lund, Lund, 222 42, Sweden

Forskningsmottagning Internmedicin (tidigare KFE), Malmo, 205 02, Sweden

CTC GoCo Mölndal, Mölndal, 431 53, Sweden

Örebro UH - Överviktsenheten, Örebro, 701 85, Sweden

Karolinska Universitetssjukhuset Solna,FOU Tema Hjärta Kärl, Stockholm, 171 64, Sweden

Taiwan

Changhua Christian Hospital_Metabolic Dept., Changhua, 500, Taiwan

Taipei Medical University Hospital, Taipei, 110, Taiwan

Turkey (Türkiye)

Cukurova Universitesi Tip Fakultesi, Adana, 01790, Turkey (Türkiye)

Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi- Endokrinoloji, Adana, 01790, Turkey (Türkiye)

Akdeniz University Tip Fakultesi Hastanesi, Antalya, 07058, Turkey (Türkiye)

Akdeniz Üniversitesi Hastanesi- Endokrinoloji, Antalya, 07058, Turkey (Türkiye)

Eskisehir Osmangazi University School of Medicine, Eskişehir, 26040, Turkey (Türkiye)

Eskişehir Osmangazi Üniversitesi Sağlık, Uygulama ve Araştırma Hastanesi, Eskişehir, 26040, Turkey (Türkiye)

Haseki Eğitim ve Araştırma Hastanesi- Dahiliye, Istanbul, 34098, Turkey (Türkiye)

Haseki Sultangazi, Istanbul, 34098, Turkey (Türkiye)

Seyrantepe Hamidiye Etfal Egitim ve Arastirma Hastanesi, Istanbul, 34371, Turkey (Türkiye)

Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi- Seyrantepe Yerleşkesi- Endokrinoloji, Istanbul, 34371, Turkey (Türkiye)

Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji, Istanbul, 34390, Turkey (Türkiye)

İstanbul Üniversitesi İstanbul Tıp Fakültesi Hastanesi- Endokrinoloji, Istanbul, 34390, Turkey (Türkiye)

Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, 34480, Turkey (Türkiye)

Başakşehir Çam ve Sakura Şehir Hastanesi, Istanbul, 34480, Turkey (Türkiye)

Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye, Istanbul, 34722, Turkey (Türkiye)

T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, 34722, Turkey (Türkiye)

Recep Tayyip Erdoğan Üni. Eğitim ve Araştırma Hastanesi, Rize, 53020, Turkey (Türkiye)

Recep Tayyip Erdoğan Üniversitesi EAH-Endokrinoloji, Rize, 53020, Turkey (Türkiye)

Tekirdag Namık Kemal UTF, Tekirdağ, 59030, Turkey (Türkiye)

Tekirdağ Namık Kemal Üniversitesi Hastanesi- Dahiliye, Tekirdağ, 59030, Turkey (Türkiye)

United Kingdom

Hertfordshire

Lister Hospital, Stevenage, Hertfordshire, SG1 4AB, United Kingdom

North Yorkshire

Pickering Medical Practice, Pickering, North Yorkshire, YO18 8BL, United Kingdom

Aberdeen Royal Infirmary - Diabetes, Aberdeen, AB25 2ZP, United Kingdom

Aberdeen Royal Infirmary, Aberdeen, AB25 2ZP, United Kingdom

Oldfield Surgery, Bath, BA2 3HT, United Kingdom

Oakenhurst Medical Practice, Blackburn, BB2 1AX, United Kingdom

Ninewells Hospital, Dundee, DD1 9SY, United Kingdom

Aintree University Hospital, Liverpool, L9 7AL, United Kingdom

Norfolk and Norwich University Hospital Trust, Norwich, NR4 7UY, United Kingdom

Moorgreen Hospital, Southampton, SO30 3JB, United Kingdom

Joint Clinical Research Facility - Swansea, Swansea, SA2 8PP, United Kingdom

Royal Cornwall Hospital (Treliske), Truro, TR1 3LJ, United Kingdom

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2) Phase 3 2,734

Inclusion Criteria

Exclusion Criteria